SCHEMBL15017289

SCHEMBL15017289

FC(F)c1cc(Cl)nc2[nH]nc(I)c12

nearest known ligand 0.36

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
JAK1 P23458 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20389658 0.75 CYP2C19 (0.37) JAK1
SCHEMBL15016940 0.74 ADORA3 (0.33)
SCHEMBL30682140 0.71 HPGD (0.35)
SCHEMBL28412458 0.71 HPGD (0.35)
SCHEMBL16476633 0.70 KDM4E (0.33)
SCHEMBL14769541 0.69 AHR (0.35)
SCHEMBL16341884 0.67 KDM4E (0.46)
SCHEMBL15016943 0.67 PLK4 (0.38)
SCHEMBL31313054 0.66 JAK1 (0.33) JAK1
SCHEMBL30367579 0.65 PDPK1 (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106317056-B Pyrazolopyrimidine derivatives, process for their preparation and their therapeutic use 赛诺菲 2020-06-23 CN disclosed
EP-2791137-B1 PYRAZOLOPYRIDINE DERIVATIVES, PREPARATION PROCESS THEREFOR AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2019-01-23 EP disclosed
US-10138235-B2 Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof SANOFI (FR) 2018-11-27 US disclosed
EP-3007694-B1 PYRAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF BLADDER CANCER SANOFI SA (FR) 2018-07-18 EP disclosed
US-20170231998-A1 Pyrazolopyridine Derivatives, Preparation Process Therefor And Therapeutic Use Thereof SANOFI (FR) 2017-08-17 US disclosed
US-20170174681-A1 Pyrazolopyridine Derivatives, Preparation Process Therefor And Therapeutic Use Thereof SANOFI (FR) 2017-06-22 US disclosed
US-9572799-B2 Pyrazolopyridine derivatives for use in the treatment of bladder cancer SANOFI (FR) 2017-02-21 US disclosed
US-20160128989-A1 PYRAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF BLADDER CANCER SANOFI (FR) 2016-05-12 US disclosed
EP-3007694-A1 PYRAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF BLADDER CANCER SANOFI (FR) 2016-04-20 EP disclosed
WO-2014198942-A1 PYRAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF BLADDER CANCER SANOFI (FR) 2014-12-18 WO disclosed
US-20140350006-A1 Pyrazolopyridine Derivatives, Preparation Process Therefor And Therapeutic Use Thereof SANOFI (FR) 2014-11-27 US disclosed
EP-2791137-A1 PYRAZOLOPYRIDINE DERIVATIVES, PREPARATION PROCESS THEREFOR AND THERAPEUTIC USE THEREOF SANOFI (FR) 2014-10-22 EP disclosed
WO-2013087744-A1 PYRAZOLOPYRIDINE DERIVATIVES, PREPARATION PROCESS THEREFOR AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-06-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160128989-A1 PYRAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF BLADDER CANCER DPYD, QDPR, UROD JAK1 1720/4885
US-20170174681-A1 Pyrazolopyridine Derivatives, Preparation Process Therefor And Therapeutic Use Thereof FGF1, FGF2, FGFR1 JAK1 245/4885
US-10138235-B2 Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof FGF1, FGF2, FGFR1 JAK1 245/4885
US-20170231998-A1 Pyrazolopyridine Derivatives, Preparation Process Therefor And Therapeutic Use Thereof FGF1, FGF2, FGFR1 JAK1 245/4885
US-20140350006-A1 Pyrazolopyridine Derivatives, Preparation Process Therefor And Therapeutic Use Thereof FGF1, FGF2, FGFR1 JAK1 245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.